Understanding gene-regulating condensates in multiple myeloma
Official title: Project 2: Investigating regulation of transcriptional condensates in multiple myeloma
Funded at Dana-Farber Cancer Inst · NIH-11389122 · Data updated 2026-11-12
This project looks at how small clumps of gene-regulating molecules affect multiple myeloma cells to point toward new treatment ideas for people with the disease.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2011 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $80,857 |
| NIH project number | 3P01CA155258-13S1 |
| Project ID | NIH-11389122 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants would be people with multiple myeloma who can provide clinical samples (for example bone marrow or tumor material) or who receive care at Dana-Farber or its partner clinics.
✕Less likely to help
People without multiple myeloma or those seeking immediate changes to their treatment are unlikely to get direct benefit from this basic-science work.
What this research studies
Researchers are studying how transcriptional condensates—tiny assemblies of proteins and RNA that control gene activity—work in multiple myeloma cells. They combine experiments in the lab with analysis of patient-derived samples to see which condensates drive cancer growth. The team uses molecular tools to change condensate behavior and measures how myeloma cells respond. Findings may guide development of drugs that target these gene-regulating structures.
Why it matters
Potential benefit: If successful, this work could reveal new molecular targets and lead to therapies that more precisely stop myeloma cell growth.
How similar studies have gone: Targeting transcriptional condensates is a relatively new approach with promising laboratory results but limited clinical proof so far.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Young, Richard — Dana-Farber Cancer Inst
- Study coordinator: Young, Richard
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.